ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals reported Q2 2025 results that exceeded revenue expectations, with sales up 53.1% year-over-year, and lifted its full-year revenue guidance. The company announced Q3 2025 earnings, reporting an EPS of $2.04, which topped analysts' consensus estimates. ANI Pharmaceuticals reported preliminary full-year 2025 results, expecting total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above prior guidance ranges, and provided bullish full-year 2026 guidance, targeting over $1 billion in revenue, leading to a stock surge of +10.6%. Over the past 90 days, ANI Pharmaceuticals' stock has seen 2 downgrades and 1 upgrade by analysts, with a consensus rating of "Moderate Buy" and an average 12-month price target of $103.43. Valuation discussions suggest mixed perspectives, with some analyses indicating undervaluation based on discounted cash flow models, while others point to a higher P/E ratio than the industry average.

ANI Pharmaceuticals' management has indicated that strong performance, particularly in its Rare Disease business, reflects underlying demand rather than seasonality or one-time benefits. Demand for their products and services is not significantly impacted by seasonal fluctuations. The accelerating demand for Cortrophin Gel and continued strength in the generics portfolio are driven by factors other than seasonal patterns.

ANI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing high-quality prescription pharmaceuticals in the United States and internationally. The company operates across three main business segments: Rare Disease, Generics, and Established Brands, with a mission to serve patients and improve lives by providing access to critical medicines that address unmet medical needs. Its major products include Purified Cortrophin Gel, a flagship rare disease product used to treat various conditions, ILUVIEN and YUTIQ, ophthalmology products acquired in 2024, and a robust portfolio of over 116 generic products.

ANI Pharmaceuticals has a significant U.S. manufacturing footprint, with over 90% of its total company revenues derived from finished goods manufactured in the U.S. The company operates manufacturing facilities in East Windsor, New Jersey, and Baudette, Minnesota, which are capable of producing various pharmaceutical formulations. While primarily U.S.-focused, the company also markets its products internationally.

ANI Pharmaceuticals emphasizes a patient-centric mission of "Serving Patients, Improving Lives," which drives its strategic business segments. The company's cultural DNA is built on a commitment to quality and ethical conduct. Its focus on addressing unmet medical needs through innovative therapeutics and consistent, reliable supply contributes to its reputation. Over the past year, there have been no specific public events reported that have negatively impacted ANI Pharmaceuticals' brand reputation beyond the general competitive and regulatory landscape inherent in the pharmaceutical industry.

ANI Pharmaceuticals, Inc.'s ownership structure is heavily weighted toward institutional investors, who hold the majority of the company's stock. As of February 4, 2026, 492 institutional owners and shareholders hold a total of 24,704,448 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., iShares Core S&P Small-Cap ETF (IJR), State Street Corp., Global Alpha Capital Management Ltd., Citadel Advisors Llc., Dimensional Fund Advisors Lp., and Geode Capital Management, Llc. Institutional investors hold approximately 76.05% of the stock, corporate insiders hold 11.10%, and the retail/general public holds 12.85%.